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Shepherd FA, Rosell R: “Weighing Tumor Biology in Treatment Decisions for Patients with Non-Small Cell Lung Cancer.”
J Thorac Oncol 2007;suppl. 2:S68–S76.
The Journal of Thoracic Oncology regrets an error in the article, “Weighing Tumor Biology in Treatment Decisions for
Patients with Non-Small Cell Lung Cancer,” which was published in a supplement to JTO in June 2007 (supplement 2).
The lines in Figures 1, 4, and 5 were mislabeled. The correct figures can be found below and in the online version of this
article. In addition, there is a typographical error on page S70: L8568R should be L858R.
FIGURE 1. Survival According to Epidermal Growth Factor Receptor Genotype.
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FIGURE 4. Survival by Epidermal Growth Factor Receptor (EGFR) protein expression and treatment for patients in BR.21
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We regret any confusion or inconvenience this may have caused, and have corrected the article as published on jto.org.
FIGURE 5. Survival by Epidermal Growth Factor Receptor (EGFR) gene copy number and treatment for patients in BR.21
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